[Clinical studies of ifosfamide for gynecological malignancies].
This study was performed to evaluate the clinical effect and the side effect of ifosfamide in the treatment of gynecological malignancies. A total of 18 cases were treated with ifosfamide: 11 of them were treated as a single agent and the remaining 7 cases were treated as a combination chemotherapy. A daily dose of 1.5-2.0 grams were given for 5 consecutive days. The number of course varied from one to five. Six (35.3%) out of 17 evaluable cases showed partial response. Three were treated with ifosfamide alone and the another three were with a combination chemotherapy. The side effect such as leukopenia, gastrointestinal disturbance and general malaise were frequently observed. Chemical cystitis (hematuria) could be prevented by adequate water intake.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D003520:Cyclophosphamide; D007069:Ifosfamide